Dr. Dean Kereiakes knows a thing or 2 about coronary stents – he’s been a principal investigator in a number of clinical trials evaluating coronary stents over the past 20 years. So it counts when Kereiakes names the Synergy stent made by Boston Scientific‘s (NYSE:BSX) “the safest stent yet.”
An interventional cardiologist at the Christ Hospital, he was also a principal investigator in Boston Scientific’s 1,684-patient Evolve II trial, comparing the Synergy bioresorbable-polymer stent with the Promus Element Plus device. The study’s primary endpoint was target lesion failure at 12 months.
Get the full story at our sister site, Drug Delivery Business News.
The post Cardiologist Dr. Kereiakes: the Synergy bioabsorbable stent boasts flexibility & safety appeared first on MassDevice.
from MassDevice http://ift.tt/2nsrBN8
Cap comentari:
Publica un comentari a l'entrada